1 |
Bembridge, G. P., Rodriguez, N., Garcia-Beato, R., Nicolson,
C., Melero, J. A. and Taylor, G. (2000) Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein. Vaccine 19, 1038-1046.
DOI
ScienceOn
|
2 |
Groothuis, J. R., King, S. J., Hogerman, D. A., Paradiso, P.
R. and Simoes, E. A. (1998) Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J. Infect. Dis. 177, 467-469.
DOI
ScienceOn
|
3 |
de Waal, L., Power, U. F., Yuksel, S., van Amerongen, G.,
Nguyen, T. N., Niesters, H. G., de Swart, R. L. and
Osterhaus, A. D. (2004) Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge. Vaccine 22, 915-922.
DOI
ScienceOn
|
4 |
Power, U. F., Nguyen, T. N., Rietveld, E., de Swart, R. L.,
Groen, J., Osterhaus, A. D., de Groot, R., Corvaia, N.,
Beck, A., Bouveret-Le-Cam, N. and Bonnefoy, J. Y. (2001)
Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J. Infect Dis. 184, 1456-1460.
DOI
ScienceOn
|
5 |
Kohlmann, R., Schwannecke, S., Tippler, B., Ternette, N.,
Temchura, V. V., Tenbusch, M., Uberla, K. and Grunwald,
T. (2009) Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. J. Virol. 83, 12601- 12610.
DOI
ScienceOn
|
6 |
Yu, J. R., Kim, S., Lee, J. B. and Chang, J. (2008) Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J. Virol. 82, 2350-2357.
DOI
ScienceOn
|
7 |
Hsu, K. H., Lubeck, M. D., Davis, A. R., Bhat, R. A.,
Selling, B. H., Bhat, B. M., Mizutani, S., Murphy, B. R.,
Collins, P. L., Chanock, R. M. and Hung, P. P. (1992) Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee. J. Infect Dis. 166, 769-775.
DOI
ScienceOn
|
8 |
Takimoto, T., Hurwitz, J. L., Zhan, X., Krishnamurthy, S.,
Prouser, C., Brown, B., Coleclough, C., Boyd, K., Scroggs,
R. A., Portner, A. and Slobod, K. S. (2005) Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus. Viral. Immunol. 18, 255-266.
DOI
ScienceOn
|
9 |
Murphy, B. R., Sotnikov, A. V., Lawrence, L. A., Banks, S.
M. and Prince, G. A. (1990) Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 8, 497-502.
DOI
ScienceOn
|
10 |
Murphy, B. R., Sotnikov, A., Paradiso, P. R., Hildreth, S.
W., Jenson, A. B., Baggs, R. B., Lawrence, L., Zubak, J. J.,
Chanock, R. M., Beeler, J. A. and Prince, G. A. (1989)
Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine 7, 533-540.
DOI
ScienceOn
|
11 |
Prince, G. A., Denamur, F., Deschamps, M., Garcon, N.,
Prieels, J. P., Slaoui, M., Thiriart, C. and Porter, D. D.
(2001) Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease. Vaccine 19, 2048-2054.
DOI
ScienceOn
|
12 |
Hancock, G. E., Heers, K. M., Pryharski, K. S., Smith, J. D.
and Tiberio, L. (2003) Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus. Vaccine 21, 4348-4358.
DOI
ScienceOn
|
13 |
Hancock, G. E., Speelman, D. J., Heers, K., Bortell, E.,
Smith, J. and Cosco, C. (1996) Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J. Virol. 70, 7783-7791.
|
14 |
Wright, P. F., Karron, R. A., Belshe, R. B., Thompson, J.,
Crowe, J. E. Jr., Boyce, T. G., Halburnt, L. L., Reed, G. W.,
Whitehead, S. S., Anderson, E. L., Wittek, A. E., Casey, R.,
Eichelberger, M., Thumar, B., Randolph, V. B., Udem, S.
A., Chanock, R. M. and Murphy, B. R. (2000) Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. 182, 1331-1342.
DOI
ScienceOn
|
15 |
Karron, R. A., Wright, P. F., Belshe, R. B., Thumar, B.,
Casey, R., Newman, F., Polack, F. P., Randolph, V. B.,
Deatly, A., Hackell, J., Gruber, W., Murphy, B. R. and
Collins, P. L. (2005) Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 191, 1093-1104.
DOI
ScienceOn
|
16 |
Wright, P. F., Karron, R. A., Madhi, S. A., Treanor, J. J.,
King, J. C., O'Shea, A., Ikizler, M. R., Zhu, Y., Collins, P.
L., Cutland, C., Randolph, V. B., Deatly, A. M., Hackell, J.
G., Gruber, W. C. and Murphy, B. R. (2006) The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J. Infect Dis. 193, 573-581.
DOI
ScienceOn
|
17 |
Tebbey, P. W., Hagen, M. and Hancock, G. E. (1998)
Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J. Exp. Med. 188, 1967-1972.
DOI
|
18 |
Johnson, T. R., Varga, S. M., Braciale, T. J. and Graham,
B. S. (2004) Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin- inactivated RSV. J. Virol. 78, 8753-8760.
DOI
ScienceOn
|
19 |
Openshaw, P. J., Clarke, S. L. and Record, F. M. (1992)
Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int. Immunol. 4, 493-500.
DOI
ScienceOn
|
20 |
Nicholas, J. A., Rubino, K. L., Levely, M. E., Adams, E. G.
and Collins, P. L. (1990) Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins. J. Virol. 64, 4232-4241.
|
21 |
Heidema, J., de Bree, G. J., De Graaff, P. M., van Maren,
W. W., Hoogerhout, P., Out, T. A., Kimpen, J. L. and van Bleek, G. M. (2004) Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes. J. Gen. Virol. 85, 2365-2374.
DOI
ScienceOn
|
22 |
Johnson, T. R., Johnson, J. E., Roberts, S. R., Wertz, G. W.,
Parker, R. A. and Graham, B. S. (1998) Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J. Virol. 72, 2871-2880.
|
23 |
De Swart, R. L., Kuiken, T., Timmerman, H. H., van
Amerongen, G., Van Den Hoogen, B. G., Vos, H. W.,
Neijens, H. J., Andeweg, A. C. and Osterhaus, A. D. (2002) Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J. Virol. 76, 11561-11569.
DOI
|
24 |
Connors, M., Giese, N. A., Kulkarni, A. B., Firestone, C.
Y., Morse, H. C. 3rd and Murphy, B. R. (1994) Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin- 4 (IL-4) and IL-10. J. Virol. 68, 5321-5325.
|
25 |
Levine, S., Klaiber-Franco, R., and Paradiso, P. R. (1987) Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J. Gen. Virol. 68(Pt 9), 2521-2524.
DOI
ScienceOn
|
26 |
Bastien, N., Trudel, M. and Simard, C. (1999) Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines. Vaccine 17, 832-836.
DOI
ScienceOn
|
27 |
Taylor, G., Stott, E. J., Bew, M., Fernie, B. F., Cote, P. J.,
Collins, A. P., Hughes, M. and Jebbett, J. (1984) Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology 52, 137-142.
|
28 |
Sparer, T. E., Matthews, S., Hussell, T., Rae, A. J., Garcia-
Barreno, B., Melero, J. A. and Openshaw, P. J. (1998)
Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J. Exp. Med. 187, 1921-1926.
DOI
|
29 |
Martinez, I. and Melero, J. A. (1998) Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein. J. Gen. Virol. 79(Pt 9), 2215-2220.
DOI
|
30 |
Johnson, P. R., Spriggs, M. K., Olmsted, R. A. and Collins,
P. L. (1987) The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc. Natl. Acad. Sci. U.S.A. 84, 5625-5629.
DOI
|
31 |
Johnson, S., Oliver, C., Prince, G. A., Hemming, V. G.,
Pfarr, D. S., Wang, S. C., Dormitzer, M., O'Grady, J.,
Koenig, S., Tamura, J. K., Woods, R., Bansal, G., Couchenour,
D., Tsao, E., Hall, W. C. and Young, J. F. (1997) Development of a humanized monoclonal antibody (MEDI- 493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect Dis. 176, 1215-1224.
DOI
ScienceOn
|
32 |
Graham, B. S., Bunton, L. A., Wright, P. F. and Karzon, D.
T. (1991) Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J. Clin. Invest. 88, 1026-1033.
DOI
|
33 |
Waris, M. E., Tsou, C., Erdman, D. D., Zaki, S. R. and
Anderson, L. J. (1996) Respiratory synctial virus infection in BALB/c mice previously immunized with formalininactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70, 2852-2860.
|
34 |
Alwan, W. H., Record, F. M. and Openshaw, P. J. (1992)
CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells. Clin. Exp. Immunol. 88, 527-536.
|
35 |
Kapikian, A. Z., Mitchell, R. H., Chanock, R. M., Shvedoff,
R. A. and Stewart, C. E. (1969) An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89, 405-421.
DOI
|
36 |
Murphy, B. R. and Walsh, E. E. (1988) Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion- inhibiting activity. J. Clin. Microbiol. 26, 1595-1597.
|
37 |
Mok, H., Lee, S., Utley, T. J., Shepherd, B. E., Polosukhin,
V. V., Collier, M. L., Davis, N. L., Johnston, R. E. and
Crowe, J. E. Jr. (2007) Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J. Virol. 81, 13710-13722.
DOI
ScienceOn
|
38 |
Li, X., Sambhara, S., Li, C. X., Ewasyshyn, M., Parrington,
M., Caterini, J., James, O., Cates, G., Du, R. P. and Klein,
M. (1998) Protection against respiratory syncytial virus infection by DNA immunization. J. Exp. Med. 188, 681-688.
DOI
|
39 |
Schmidt, A. C., McAuliffe, J. M., Murphy, B. R. and Collins,
P. L. (2001) Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J. Virol. 75, 4594-4603.
DOI
ScienceOn
|
40 |
Elliott, M. B., Chen, T., Terio, N. B., Chong, S. Y.,
Abdullah, R., Luckay, A., Egan, M. A., Boutilier, L. A.,
Melville, K., Lerch, R. A., Long, D., Eldridge, J. H., Parks,
C. L., Udem, S. A. and Hancock, G. E. (2007) Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques. Vaccine 25, 7132-7144.
DOI
ScienceOn
|
41 |
Cano, F., Plotnicky-Gilquin, H., Nguyen, T. N., Liljeqvist,
S., Samuelson, P., Bonnefoy, J., Stahl, S. and Robert, A.
(2000) Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides. Vaccine 18, 2743-2752.
DOI
ScienceOn
|
42 |
Martinez-Sobrido, L., Gitiban, N., Fernandez-Sesma, A.,
Cros, J., Mertz, S. E., Jewell, N. A., Hammond, S., Flano,
E., Durbin, R. K., Garcia-Sastre, A. and Durbin, J. E.
(2006) Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J. Virol. 80, 1130-1139.
DOI
ScienceOn
|
43 |
Bukreyev, A., Yang, L., Fricke, J., Cheng, L., Ward, J. M.,
Murphy, B. R. and Collins, P. L. (2008) The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor- bearing leukocytes. J. Virol. 82, 12191-12204.
DOI
ScienceOn
|
44 |
Hall, C. B., Walsh, E. E., Long, C. E. and Schnabel, K. C.
(1991) Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect Dis. 163, 693-698.
DOI
ScienceOn
|
45 |
Walsh, E. E., Hall, C. B., Briselli, M., Brandriss, M. W. and
Schlesinger, J. J. (1987) Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. J. Infect Dis. 155, 1198-1204.
DOI
ScienceOn
|
46 |
Connors, M., Collins, P. L., Firestone, C. Y. and Murphy,
B. R. (1991) Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J. Virol. 65, 1634-1637.
|
47 |
Piedra, P. A., Cron, S. G., Jewell, A., Hamblett, N.,
McBride, R., Palacio, M. A., Ginsberg, R., Oermann, C.
M. and Hiatt, P. W. (2003) Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine 21, 2448-2460.
DOI
ScienceOn
|
48 |
Tristram, D. A., Welliver, R. C., Mohar, C. K., Hogerman,
D. A., Hildreth, S. W. and Paradiso, P. (1993) Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J. Infect. Dis. 167, 191-195.
DOI
ScienceOn
|
49 |
Chang, J. and Braciale, T. J. (2002) Respiratory syncytial virus infection suppresses lung CD8+ T-cell effector activity and peripheral CD8+ T-cell memory in the respiratory tract. Nat. Med. 8, 54-60.
DOI
ScienceOn
|
50 |
Schlender, J., Walliser, G., Fricke, J. and Conzelmann, K.
K. (2002) Respiratory syncytial virus fusion protein mediates inhibition of mitogen-induced T-cell proliferation by contact. J. Virol. 76, 1163-1170.
DOI
|
51 |
Pringle, C. R., Filipiuk, A. H., Robinson, B. S., Watt, P. J.,
Higgins, P. and Tyrrell, D. A. (1993) Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine 11, 473-478.
DOI
ScienceOn
|
52 |
Henderson, F. W., Collier, A. M., Clyde, W. A. Jr. and
Denny, F. W. (1979) Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N. Engl. J. Med. 300, 530-534.
DOI
ScienceOn
|
53 |
Johnson, T. R., Teng, M. N., Collins, P. L. and Graham, B.
S. (2004) Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J. Virol. 78, 6024-6032.
DOI
ScienceOn
|
54 |
Crowe, J. E. Jr., Firestone, C. Y. and Murphy, B. R. (2001)
Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J. Immunol. 167, 3910-3918.
DOI
|
55 |
Glezen, W. P., Taber, L. H., Frank, A. L. and Kasel, J. A.
(1986) Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140, 543-546.
|
56 |
Srikiatkhachorn, A. and Braciale, T. J. (1997) Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med. 186, 421-432.
DOI
|
57 |
Martinez, I., Dopazo, J. and Melero, J. A. (1997) Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants. J. Gen. Virol. 78(Pt 10), 2419-2429.
DOI
|
58 |
Connors, M., Kulkarni, A. B., Collins, P. L., Firestone, C.
Y., Holmes, K. L., Morse, H. C. 3rd and Murphy, B. R.
(1992) Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies. J. Virol. 66, 1277-1281.
|